Pharaoh Neuro — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Pharaoh Neuro is an early-stage medical device innovator targeting the high-need neurocritical care market with its Neurapheresis™ extracorporeal CSF filtration system. The company is currently conducting the PILLAR-XT clinical trial to evaluate the safety and efficacy of its platform for patients with subarachnoid hemorrhage and recently secured a $20 million Series A financing round. Led by a team with deep medtech and neurosurgical expertise, and backed by experienced founders from Minnetronix Medical, Pharaoh Neuro is positioned to advance a novel therapeutic approach for a condition with significant unmet need and catastrophic outcomes.

Neurocritical CareCerebrovascular

Technology Platform

Neurapheresis™: an extracorporeal platform for the precision filtration and management of cerebrospinal fluid (CSF) to remove harmful substances like blood and its breakdown products.

Opportunities

The primary opportunity is addressing the catastrophic unmet need in aneurysmal subarachnoid hemorrhage (aSAH) by directly removing toxic blood from the CSF, potentially preventing secondary injuries and improving survival and functional outcomes.

Success in aSAH can serve as a beachhead to expand the Neurapheresis™ platform into other large neurocritical care indications like traumatic brain injury and intraventricular hemorrhage, creating a new therapeutic category in neurology.

Risk Factors

Key risks include clinical trial failure to demonstrate safety or efficacy, regulatory hurdles in obtaining FDA clearance, and challenges in commercial adoption within complex hospital ICU settings.

The company also faces competition risk from larger medtech firms and execution risk in scaling its technology and operations.

Competitive Landscape

The competitive landscape for direct CSF filtration in aSAH is nascent, with few, if any, directly comparable commercial devices, giving Pharaoh Neuro a first-mover advantage. However, it competes indirectly with the standard of supportive care and other investigational approaches for vasospasm. Broader competition includes large medtech companies with neurovascular portfolios (e.g., Stryker, Medtronic) who could develop or acquire similar technologies.

More companies in Neuroscience & CNS →More companies in United States →